secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2026-09-29T21:00:13+00:00
Accession:  0001193125-26-407728
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Heron Therapeutics licenses Long Grove products for US sale; pays undisclosed milestones and royalties
--------------------------------------------------------------------------------

- Sept 23, 2026 Development and License Agreement with Long Grove Pharmaceuticals, LLC and Capstone Development Services Company, LLC.
- Heron gets exclusive (as to licensed patents), sublicensable US rights to import, distribute, sell and market certain products.
- Heron also gets a non-exclusive worldwide license to manufacture those products for sale in the Territory.
- Heron owes regulatory milestone payments, sales-based milestones, royalties and expense reimbursement; no dollar amounts were disclosed.
- Initial 10-year term from first commercial sale, automatic 2-year renewals; agreement to be filed with the Q3 2026 Form 10-Q.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000119312526407728/0001193125-26-407728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000119312526407728/hrtx-20260923.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-407728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer